A Real World Post-Marketing Surveillance Study Assessing the Safety and Efficacy of Teneligliptin in Japanese Patients with Type 2 Diabetes Mellitus (T2DM)
Phase of Trial: Phase IV
Latest Information Update: 23 Dec 2019
Price : $35 *
At a glance
- Drugs Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms RUBY
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 23 Dec 2019 Status changed from active, no longer recruiting to completed, according to results published in the Advances in Therapy Journal.
- 23 Dec 2019 Results assessing the 3-year safety and efficacy of teneligliptin in this study, were published in the Advances in Therapy Journal.
- 01 Jun 2018 Interim results (data cut off: 28 Jun, 2017; n=11,425) published in the Diabetes Therapy.